tbuckley/cabot-search huggingface dataset:
Papillomatosis cutis arising on an immuno-compromised district due to paraplegia
Authors: A. Baroni, V. Ruocco, R. Di Maio, T. Nuzzo, M. Del Vecchio, E. Ruocco
Journal: British Journal of Dermatology (2010)

Conflicts of interest: none declared. Madam, The immunocompromised district is a novel concept referring to a site in which there is an obstacle to the normal trafficking of immunocompetent cells through lymphatic channels, or an interference with the signals that the neuropeptides and neurotransmitters, released by peripheral nerves, send to cell membrane receptors of immunocompetent cells.1 While congenital and acquired immunodeficiencies represent the prototypes of generalized immunosuppression paving the way to systemic diseases, regional chronic lymphoedema, herpes‐infected sites and otherwise damaged areas are clear examples of locally immunocompromised cutaneous districts which are prone to developing circumscribed immunity‐related disorders (malignant tumours, opportunistic infections and immune disorders).1 Cutaneous regions that have been affected by chronic lymphoedema, herpes infection and traumas, such as areas that have undergone various physical injuries (ionizing or ultraviolet radiation, thermal burns, vaccinations), share one common feature: the propensity to harbour a secondary disease, which can appear after an extremely variable lapse of time (days, months, years, decades) on the altered site.2
Abstract 12164: Circulating Levels of Biomarkers of Collagen Synthesis Correlate with Left Ventricular Mechanical Dyssynchrony in Adolescents after Repair of Tetralogy of Fallot
Authors: Clare Tm Lai, Koon-wing Chan, Sophia J Wong, Pak-cheong Chow, Yiu-fai Cheung
Journal: Circulation (2010)

Core 5. Myocardium: Function and Failure - Session Title: Biomarkers in Heart Failure: abstract A12164
A Dictionary of Slang and Colloquial English. Abridged from the seven-volume work entitled, Slang and Its Analogues.
Authors: John Stephen Farmer, William Ernest Henley
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Implementation assessment of the 70-gene prognosis signature for breast cancer diagnostics
Authors: V. Retel, J. Bueno de Mesquita, L. van't Veer, M. J. van de Vijver, S. C. Linn, M. Hummel, W. van Harten
Journal: Journal of Clinical Oncology (2008)

6575 Background: A Constructive Technology Assessment (CTA) in the early phase of controlled implementation of the 70-gene prognosis signature (MammaPrint™) for node-negative breast cancer in community hospitals in The Netherlands (van de Vijver et al, 2002) as part of the prospective MicroarRAy PrognoSTics in Breast CancER (RASTER) study (Bueno de Mesquita et al, 2007). Methods: A multi-center, pre-post controlled prospective study between 2004–2006, using CTA. Four aspects were studied: I) Clinical effectiveness: treatment advice based on guidelines, and/or prognosis signature versus actual treatment decision. II) Efficiency: pre-post structured surveys in participating hospitals concerning changes in logistics and teamfunctioning. III) Patient centeredness: questionnaires and interviews on involvement in decision making and psychological impact. IV) Scenario: involvement of scientific and medical-oncology professionals as a way to anticipate diffusion and possible future developments. Results: I) Out of 812 patients, 427 signatures were obtained, 30% was discordant (guidelines versus signature), which resulted in change of treatment in 54% of the discordant cases. II) Surveys were performed in 15 hospitals. Duration of implementation varied from 0.2–9.4 months (mean 2.2). Most changes were seen in pathology processes and multidisciplinary teammeetings concerning adjuvant treatment decision. III) 77 patients were interviewed or returned a questionnaire (response 78%). High risk and discordant clinical low/poor signature patients showed significantly more negative emotions compared to low risk patients. Dissatisfaction was expressed by discordant patients, caused by the successive communication of the two risk assessments. IV) Scenario drafting will lead to input for model-based cost-effectiveness analysis. Conclusions: Introduction of the 70-gene signature showed 30% discordance, differences in implementationspeed and influenced treatment decisions. Impact on patients seems especially related to discordance and the successive communication. Physicians valued the addition of the 70-gene signature information as beneficial for patient management. CTA is appropriate for the study of early implementation of this technology. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Agendia Agendia
Abstract 1918: Prevalence of Myocardial Infarction After Heart Transplantation Detected by Contrast Enhanced MRI
Authors: Henning Steen, Sonja Refle, Constanze Merten, Thomas Dengler, Hugo A Katus, Evangelos Giannitsis
Journal: Circulation (2006)

Background: Transplant coronary artery disease (TCAD) limits long-term survival after heart transplantation (HTX). X-ray angiography tends to underestimate the degree of TCAD and often underdiagnos...
Oesophageal involvement in bullous pemphigoid.
Authors: TIN Y. ENG, WALTER J. HOGAN, ROBERT E. JORDON
Journal: British Journal of Dermatology (1978)

Journal Article Oesophageal involvement in bullous pemphigoid: A POSSIBLE CAUSE OF GASTROINTESTINAL HAEMORRHAGE Get access TIN Y. ENG, TIN Y. ENG Department of Medicine, Sections of Dermatology and Gastroenterology, The Medical College of Wisconsin, Milwaukee, Wisconsin, U.S.A. Search for other works by this author on: Oxford Academic Google Scholar WALTER J. HOGAN, WALTER J. HOGAN Department of Medicine, Sections of Dermatology and Gastroenterology, The Medical College of Wisconsin, Milwaukee, Wisconsin, U.S.A. Search for other works by this author on: Oxford Academic Google Scholar ROBERT E. JORDON ROBERT E. JORDON Department of Medicine, Sections of Dermatology and Gastroenterology, The Medical College of Wisconsin, Milwaukee, Wisconsin, U.S.A. Reprint requests: Dr R. E. Jordon, VA Hospital, Dermatology Section, 5000 W. National Avenue, Wood, Wisconsin 53193, U.S.A. Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 99, Issue 2, 1 August 1978, Pages 207–210, https://doi.org/10.1111/j.1365-2133.1978.tb01984.x Published: 01 August 1978
The novel protease inhibitor SRD441 ointment is not effective in the treatment of adult subjects with atopic dermatitis: results of a randomized, vehicle‐controlled study
Authors: R. Foelster Holst, S. Reitamo, R. Yankova, M. Worm, M. Kadurina, K. Thaci, T. Bieber, N. Tsankov, A. Enk, T. Luger, M. Duffy, R. Tansley
Journal: Allergy (2010)

To cite this article: Foelster Holst R, Reitamo S, Yankova R, Worm M, Kadurina M, Thaci K, Bieber T, Tsankov N, Enk A, Luger T, Duffy M, Tansley R. The novel protease inhibitor SRD441 ointment is not effective in the treatment of adult subjects with atopic dermatitis: results of a randomized, vehicle‐controlled study. Allergy 2010; 65 : 1594–1599. Abstract Background: There is evidence that excessive protease activity in the skin is an important factor in the development of atopic dermatitis. SRD44 is a topically formulated novel protease inhibitor that selectively inhibits Staphylococcal‐ derived aureolysin and matrix metalloproteinases (MMPs). Methods: This was a double‐blind, vehicle‐controlled randomized trial conducted in thirteen hospital dermatology outpatient clinics in Germany (9), Bulgaria (3) and Finland (1). Ninety‐three out of 103 screened adult subjects with confirmed atopic dermatitis affecting ≤20% of body surface area, with an IGA score of 2 or 3 at randomization were randomized following a washout period to either SRD441 ointment or matching vehicle twice daily for 28 days. The primary efficacy endpoint was the clearance of Atopic dermatitis (AD score of 0 or 1 IGA) at Day 21. Secondary endpoints included measures of SCORing Atopic Dermatitis, pruritus self‐assessment, rescue medication use and occurrence of new exacerbations. A range of safety and tolerance endpoints were included. Results: There were no significant treatment differences in IGA success rates at Day 21 (SRD441 ointment, 11.1%; vehicle ointment, 12.5%; P = 1.000). Evaluation of secondary efficacy variables revealed no clinical or important statistical differences between treatment groups. Eighteen subjects (19.4%) discontinued the study drug because of an AE (seven subjects [15.6%] in the SRD441 group and 11 subjects [22.9%] in the vehicle group). Twenty‐seven subjects (60.0%) in the SRD441 group and 34 subjects (70.8%) in the vehicle group reported an adverse event (AE). Conclusions: SRD441 ointment did not demonstrate efficacy in the treatment of atopic dermatitis raising questions on the effectiveness of MMPs as a target for the treatment of atopic dermatitis. NCT00882245.
Combined penetrating keratoplasty and trabeculectomy with mitomycin C
Authors: Darrell WuDunn, Eduardo Alfonso, Paul F Palmberg
Journal: Ophthalmology (1999)

ObjectiveTo evaluate corneal graft survival and intraocular pressure control in eyes that have undergone combined penetrating keratoplasty and trabeculectomy with mitomycin C (MMC).DesignRetrospective noncomparative case series.InterventionPenetrating keratoplasty combined with trabeculectomy with MMC and other surgical procedures.ParticipantsTwenty-four eyes of 22 patients undergoing combined penetrating keratoplasty and trabeculectomy with mitomycin C.Main outcome measuresCorneal graft clarity and intraocular pressure control.ResultsThe cumulative probability of corneal graft survival was 85% at 1 year and 60% at 2 years. The cumulative probability of adequate pressure control was 67% at 3 months, 55% at 12 months, and 50% at 24 months. The incidence of bleb failure was higher in cases involving additional concomitant procedures, such as anterior vitrectomy, lens implantation or exchange, and drainage tube implantation.ConclusionsCombined penetrating keratoplasty and trabeculectomy with mitomycin C is associated with good corneal graft survival but also a risk of early failure of intraocular pressure control. Other concomitant procedures during the combined penetrating keratoplasty/trabeculectomy may increase the risk of early bleb failure.
Magnetic Resonance Imaging in Cardiac Amyloidosis&amp;#x204E;&amp;#x204E;Editorials published in JACC: Cardiovascular Imaging reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Imaging or the American College of Cardiology.
Authors: Dudley J. Pennell, Alicia M. Maceira
Journal: JACC. Cardiovascular imaging (2009)
Abstract 21366: Incidence and Causes of Sudden Death in the Young, Results of the First Year of the Careful Study
Authors: Anneke Hendrix, Christian van der Werf, Arend Mosterd, Aryan Vink, Michiel L Bots, Pieter A Doevendans, Arthur A Wilde, Irene M van Langen
Journal: Circulation (2010)

Background: Sudden cardiac death in the young (1-45 y) is a strong risk factor for the presence of inherited cardiac diseases in surviving first-degree relatives. The purpose of the current study i...
Abstract 3839: Oxidative damage in predicting early adverse skin reactions from adjuvant radiotherapy in a tri-racial/ethnic breast cancer population
Authors: Omar L. Nelson, Cristiane Takita, Jean Wright, Eunkyung Lee, Jennifer J. Hu
Journal: Cancer Research (2014)

Abstract Adjuvant radiotherapy (RT) following breast conservation surgery has significantly improved survival. However, may patients develop adverse skin reactions, pain, breast edema and poor cosmetic results that impact quality of life. Inter-individual variability in the development of RT-induced adverse reactions in normal tissue is well-documented for both acute and late effects. Therefore, we evaluated the first 161 patients in an ongoing prospective study of conservatively managed breast cancer patients using the NCI CTCAE v3.0 criteria. We recorded patient characteristics, smoking history, body mass index (BMI), and treatments. We pilot tested urinary 8-hydroxydeoxyguanosine (8-OHdG) as an oxidative damage marker in predicting RT-induced skin toxicity. Women younger than 50 years of age had a significantly (p=0.016) higher post-RT skin toxicity (grade 2); higher proportion of African Americans have grade 3 skin (p=0.008) compared to other races; and obesity (BMI&amp;gt;30) was associated with worse skin toxicity. In multivariate analysis, women with a higher pre-RT 8-OHdG had a significantly higher risk of worse skin toxicity at week 3 (OR=11.77; 95C%CI=1.21-114.45; p=0.034). Obesity (BMI&amp;gt;30) was associated with worse skin toxicity at the end of RT (OR=2.27; 95C%CI=1.14-4.50; p=0.019). This is the first study evaluating oxidative damage in RT-induced skin toxicity. We reported significant racial/ethnic differences in urinary 8-OHdG levels and a significant association between pre-RT 8-OHdG and worse skin toxicity at week 3. If confirmed in our larger ongoing study of 1,255 patients, our study will lead to effective treatment strategies and improve quality of life of breast cancer patients undergoing RT. Citation Format: Omar L. Nelson, Cristiane Takita, Jean Wright, Eunkyung Lee, Jennifer J. Hu. Oxidative damage in predicting early adverse skin reactions from adjuvant radiotherapy in a tri-racial/ethnic breast cancer population. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3839. doi:10.1158/1538-7445.AM2014-3839
Abstract 174: Remote Ischemic Preconditioning Improves Digital Vascular Endothelial Function and Enhances Circulating Nitric Oxide Formation in Healthy Volunteers
Authors: Jun Tao, Xinzhu Tong
Journal: Circulation (2014)

Background: Remote ischemic preconditioning (RIPC) induced by brief episodes of ischemia of the limb protects against organ damage by ischemia-reperfusion. It has been reported that RIPC improves endothelial function of the forearm in normal subjects and patients with coronary artery disease. However, the digital vascular endothelial response to RIPC has not been determined in healthy volunteers. Methods: This study was performed to examine effect of RIPC on fingertip digital vascular endothelial function by using endothelial pulse amplitude tonometry (EndoPAT) device and alteration in circulating nitric oxide(NO) level in peripheral blood. Ten healthy adult subjects (5 men, 5 women, mean age 25.2 years) had 3 cycles of 5 min ischemia alternating with 5 min reperfusion of the forearm. Another 10 healthy volunteers (6 men, 4 women, mean age 26.2 years) were used as the control group of sham and the cuff was inflated for 3 times at 10 mmHg for 5 minutes with 5-minute intervals. Fingertip digital vascular endothelial function of the ipsilateral arm was measured prior to first ischemia, 3h and 6h after the last episode of ischemia. Blood samples were taken from the contralateral arm prior to first ischemia, 3h and 6h after the last episode of ischemia. Results: Fingertip digital vascular endothelial function was significantly increase in 3h and 6h after the last RIPC intervention compared with the baseline condition(p&lt;0.05). In parallel the RIPC stimulus increased circulating NO formation(p&lt;0.05). There is a close association between finger vascular endothelial function and NO formation(p&lt;0.05). Conclusion: The present findings demonstrate for the first time that transient RIPC contributes to improvement of digital vascular endothelial function and increase in circulating NO production in healthy volunteers. Our data provide a novel evidence to support that RIPC might gain even wider application not only in disease but also in health.
Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy
Authors: K. Papp, J. Crowley, J.-P. Ortonne, J. Leu, M. Okun, S.R. Gupta, Y. Gu, R.G. Langley
Journal: British Journal of Dermatology (2010)

Background Adalimumab is effective for moderate to severe chronic plaque psoriasis; however, data regarding retreatment following withdrawal and subsequent relapse are limited. Objectives To evaluate the efficacy and safety of adalimumab if interrupted and then resumed in patients with moderate to severe psoriasis. Methods Patients in a long-term adalimumab open-label extension study (NCT00195676) who achieved a Physician’s Global Assessment (PGA) score of ‘Mild’ (2), ‘Minimal’ (1) or ‘Clear’ (0) were withdrawn from adalimumab and monitored for relapse to PGA of ‘Moderate’ (3) or worse. The subgroup of interest had stable psoriasis control, defined as PGA of 0/1 for ≥ 12 weeks on every other week (eow) dosing before withdrawal. Relapsing patients were retreated with adalimumab (80 mg at week 0 and 40 mg eow starting at week 1). PGA, Psoriasis Area and Severity Index responses, fatigue, pharmacokinetics and immunogenicity were assessed. Results In total, 525 patients were withdrawn from adalimumab; the subgroup with stable psoriasis control comprised 285 patients. Of these, 178 relapsed (median = 141 days) before treatment reinitiation and 107 did not relapse. Patients without relapse by 40 weeks off therapy reinitiated adalimumab. Rates of PGA 0/1 after 16 weeks of adalimumab retreatment were 89% for patients without relapse and 69% for patients who relapsed. Relapsers experienced significantly less fatigue after retreatment. Nine patients (3%) had serious adverse events (two were infections). No rebound or allergic reactions occurred. Conclusions Adalimumab-treated patients who discontinued therapy and subsequently relapsed had a good likelihood of regaining clinical efficacy following adalimumab reinitiation.
History of Emerging Vascular Disease Risk Factors
Authors: Laurence Pilgeram
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Bronchoscopy of peripheral lung lesions: Cost-effectiveness analysis of different combinations of sampling techniques
Authors: Kjetil Roth, Tomas Mikal Eagan, Friedemann Leh, Alf Henrik Andreassen, Jon Andrew Hardie
Journal: European Respiratory Journal (2011)

Background: Few studies have measured both the costs and the effectiveness of different combinations of sampling techniques when bronchoscopies of peripheral lung lesions are evaluated.

Objective: To find the most cost effective combination of sampling techniques for peripheral lung lesions not visible by bronchoscopy.

Methods: 289 patients were included in an open prospective trial performed at the Haukeland University Hospital and Aalesund Hospital in Norway, from June 2005 to January 2008. All sampling techniques (biopsy, brushing, trans-bronchial needle aspiration (TBNA), and washing) were performed in 178 cases (study sample). The costs from the Department of Thoracic Medicine and the Department of Pathology were calculated for each sampling technique. The combined diagnostic yield for benign and malignant disease was the effectiveness measurement. The willingness to pay for one additional positive sample was estimated to be 2800 euro, based on the cost for 5 days in a day ward and the cost of one additional investigation. The combination was cost-effective when the incremental cost-effectiveness ratio (ICER) was below the willingness to pay.

Results: The detection rate for cancer increased from 36.7% for biopsy alone to 43.8% for biopsy and brushing. The ICER was 1211 euro for biopsy and brushing compared to biopsy alone. Addition of washing or TBNA to biopsy and brushing was not cost-effective for peripheral lesions (ICER washing: 4761 euro, ICER TBNA: 8262 euro)

Conclusion: Biopsy and brushing was the most cost-effective combination of sampling techniques for peripheral lesions.
Independent Prognostic Importance of a Restrictive Left Ventricular Filling Pattern After Myocardial Infarction
Authors: Graham Hillis, J. E. Møller, G. A. Whalley, F. Dini, R. Doughty, G. D. Gamble, A. L. Klein, M. Quintana, C. M. Yu
Journal: Circulation (2008)

Restrictive mitral filling pattern (RFP), the most severe form of diastolic dysfunction, is a predictor of outcome after acute myocardial infarction (AMI). Low power has precluded a definite conclusion on the independent importance of RFP, especially when overall systolic function is preserved. We undertook an individual patient meta-analysis to determine whether RFP is predictive of mortality independently of LV ejection fraction (LVEF), end-systolic volume index, and Killip class in patients after AMI.Twelve prospective studies (3396 patients) assessing the relationship between prognosis and Doppler echocardiographic LV filling pattern in patients after AMI were included. Individual patient data from each study were extracted and collated into a single database for analysis. RFP was associated with higher all-cause mortality (hazard ratio, 2.67; 95% CI, 2.23 to 3.20; P<0.001) and remained an independent predictor in multivariate analysis with age, gender, and LVEF. The overall prevalence of RFP was 20% but was highest (36%) in the quartile of patients with lowest LVEF (<39%) and lowest (9%) in patients with the highest LVEF (>53%; P<0.0001). RFP remained significant within each quartile of LVEF, and no interaction was found for RFP and LVEF (P=0.42). RFP also predicted mortality in patients with above- and below-median end-systolic volume index (1575 patients) and in different Killip classes (1746 patients). Importantly, when diabetes, current medication, and prior AMI were included in the model, RFP remained an independent predictor of outcome.Restrictive filling is an important independent predictor of mortality after AMI regardless of LVEF, end-systolic volume index, and Killip class.